Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Idiopathic thrombocytopenic purpura

Idiopathic thrombocytopenic purpura

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Idiopathic thrombocytopenic purpura

24 trials tracked for Idiopathic thrombocytopenic purpura: 14 in phase 3 or 4 and 2 with published results. The most-cited published study has 155 citations.

24Trials tracked
14Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 13 Phase 2 9 Other / NA 1
  1. Phase 3 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed · 155 cited
  2. Phase 3 IGIV Study for Chronic ITP Patients Ages 3-70 Completed · 7 cited
  3. Phase 4 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed
  4. Phase 3 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed
  5. Phase 3 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed
  6. Phase 3 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 Completed
Show 18 more trials
  1. Phase 3 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed
  2. Phase 3 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) Completed
  3. Phase 3 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed
  4. Phase 3 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed
  5. Phase 3 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura Completed
  6. Phase 3 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed
  7. Phase 3 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP Completed
  8. Phase 3 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed
  9. Phase 2 Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) Completed
  10. Phase 2 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim Completed
  11. Phase 2 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) Completed
  12. Phase 2 Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects Completed
  13. Phase 2 Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP Completed
  14. Phase 2 Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Completed
  15. Phase 2 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Completed
  16. Phase 2 Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed
  17. Phase 2 Sirolimus for Autoimmune Disease of Blood Cells Completed
  18. N/A Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Idiopathic thrombocytopenic purpura: what the trials found

Romiplostim has demonstrated significant efficacy in improving platelet counts and achieving clinical responses. Trials showed a significant increase in the percentage of participants with durable platelet responses 2, overall platelet responses 2, and an increase in mean weekly platelet counts compared to placebo 13. Romiplostim was associated with a 32% remission rate and a low incidence of splenectomy during a 12-month treatment period 19. Additionally, Romiplostim showed a positive impact on quality of life scores (EQ-5D) 12 and demonstrated clinical utility in various phases of study [10, 15].

Eltrombopag is established as an effective intervention for increasing platelet counts. Trials reported significant improvements in the number of participants achieving a platelet count of at least 50 Gi/L over several weeks [8, 11], with some data showing high rates of patients maintaining these levels compared to baseline 11.

Rituximab demonstrated statistically significant improvements in initial response 7 and sustained response 7 for patients. Other interventions included SB-497115-GR, which showed a 43.5% responder rate over 26 weeks 14, and R788, which achieved a stable platelet response in some participants 4.

Placebo groups consistently showed lower rates of platelet response and higher rates of treatment failure or splenectomy compared to active interventions like Romiplostim and Eltrombopag [9, 13, 17].

Recent results — preliminary, needs further review

  • Rituximab (MabThera/Rituxan) showed a 43.5% rate of CR or PR in a small cohort, but this finding is not yet corroborated.
  • Sirolimus was evaluated for toxicity, but results are not yet corroborated.
  • Immune Globulin IV and Fostamatinib Disodium were studied but findings are not yet corroborated.

For the clinician treating this condition

  • Romiplostim is a highly effective option for increasing platelet counts, achieving durable responses, and reducing the need for splenectomy.
  • Eltrombopag provides significant and sustained increases in platelet counts above 50 Gi/L.
  • Rituximab shows statistically significant improvements in both initial and sustained clinical responses.

AI synthesis of 8 cited trials, updated Jul 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.